Skip to main content
ABCL
NASDAQ Life Sciences

AbCellera Reports Strong Q1 Revenue Growth, Reduced Net Loss, and Positive ABCL635 Phase 1 Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.89
Mkt Cap
$1.592B
52W Low
$1.94
52W High
$6.515
52W Position info
152% above low
Off High info
25% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

ABCL has more than doubled off its 52-week low of $1.94 on elevated volume (2.7× avg).

Summary

AbCellera Biologics reported robust Q1 2026 financial results with 96% revenue growth and a reduced net loss, alongside positive interim Phase 1 data for its lead antibody candidate, ABCL635, and a strong 36-month liquidity outlook.


Key Events · Earnings and Guidance · ABCL

  • Strong Q1 2026 Financial Performance

    Total revenue increased by 96% to $8.3 million for the three months ended March 31, 2026, compared to $4.2 million in the prior year. Net loss decreased to $43.2 million from $45.6 million year-over-year.

  • Positive Interim Phase 1 Data for Lead Candidate ABCL635

    The company announced positive interim Phase 1 data for ABCL635, showing potent and sustained reduction in biomarkers of target engagement and a favorable safety profile. Phase 2 is currently enrolling, with topline data anticipated in Q3 2026.

  • Solid Liquidity Position and Runway

    AbCellera maintains $504.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and projects sufficient liquidity to meet its needs for at least the next 36 months.

  • Strategic Shift to Internal Pipeline Development

    The company is increasingly focusing on advancing its own pipeline of antibody drug candidates, a strategic pivot that involves significant investment and inherent clinical development risks but also potential for higher value creation.


Analysis · ABCL · Life Sciences

AbCellera Biologics delivered a strong first quarter, nearly doubling revenue and reducing its net loss. The positive interim Phase 1 data for its lead antibody candidate, ABCL635, is a significant de-risking event for a clinical-stage biotech, indicating potential for a favorable safety profile and target engagement. While cash burn from operations increased, the company maintains a solid 36-month liquidity runway, providing stability for its strategic pivot towards developing its internal pipeline. The collection of a substantial litigation settlement further bolsters its financial position.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABCL was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $1.94 to $6.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABCL - Latest Insights

ABCL
Nov 09, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.54
Real-time Price: $10.10 info
Change: -$2.45 (-20%) info
Market Cap: $3.42B info
ABCL
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $10.10 info
Change: -$2.80 (-22%) info
Market Cap: $3.42B info
ABCL
Aug 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.97
Real-time Price: $10.10 info
Change: -$0.8738 (-8%) info
Market Cap: $3.42B info
ABCL
Aug 13, 2026, 12:05 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $10.32
Real-time Price: $10.10 info
Change: -$0.2238 (-2%) info
Market Cap: $3.42B info
ABCL
Aug 11, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $10.10 info
Change: +$0.7762 (+8%) info
Market Cap: $3.42B info